This study is in progress, not accepting new patients
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Aaron Logan
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Aaron Logan
Dr. Aaron Logan is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Kite, A Gilead Company
- Links
- Gilead Clinical Trials Website
- ID
- NCT02614066
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 125 people participating
- Last Updated